BOSTON, Sept. 15, 2008 (GLOBE NEWSWIRE) -- AG Mednet, the world's largest diagnostic imaging network, today announced a multi-year partnership with ConforMIS to provide the company with access to its state-of-the art, global imaging network, including managed transport services for all their external and internal image transfer needs.
ConforMIS is an orthopedic medical device company that has developed the first ever personalized knee resurfacing product line designed to conform precisely to a patient's knee. Using a proprietary technology called iFit(tm) and data from a diagnostic MR or CT scan, ConforMIS creates minimally-invasive, patient-specific implants that offer unique advantages over a traditional knee replacement for patients suffering from osteoarthritis and joint damage. Patients benefit from superior fit, significant bone preservation, less trauma and potentially faster recovery. Healthcare professionals benefit from a simplified, reproducible surgical technique and radical reduction in the number of surgical instruments that require handling and cleaning.
"It is of vital importance to us and our physicians to process patient implants with the highest level of speed, efficiency and accuracy," said Philip Licari, COO of ConforMIS. "AG Mednet's global network clearly met these needs with a simple, reliable, fast and secure way to send patient CT and MRI images from around the world."
AG Mednet's extensive network is designed to route DICOM-based diagnostic image studies ranging from standard modalities -- like CT, MRI, ultrasound, PET and digital x-ray -- to the most advanced studies -- such as IVUS and CTA/MRA. Studies of all sizes are transported lossless at the highest per-image speeds in the industry. This happens seamlessly across AG Mednet's carrier-class network, which is monitored 24x7x365 and has a record of greater than 99.9999% uptime.
"AG Mednet's software-based image submission platform, together with its global network is perfectly positioned to serve the needs of ConforMIS to receive CTs and MRIs from the U.S. as well as distant corners of the world. Working with ConforMIS continues to fulfill our vision of healthcare imaging as a global endeavor," said Abraham Gutman, CEO of AG Mednet.
About AG Mednet
AG Mednet is the world's largest diagnostic imaging network. Pharmaceutical, biotech and medical device companies, core labs and clinical research organizations (CROs) utilizing imaging technology as part of their trial protocol rely on AG Mednet's automated system to enable the secure electronic transfer of cases from hundreds of locations, enhancing site compliance while providing detailed reporting necessary to meet the most stringent regulatory requirements. Hospitals and Teleradiology providers requiring faster, more efficient, more flexible and more scalable image transport from their clients to their readers can rely on AG Mednet's dedicated, carrier-class network to route uncompressed studies of all types and sizes, as well as associated clinical data securely and efficiently through its robust fiber-optic network infrastructure. AG Mednet is headquartered in Boston and serves the global medical community. For more information call 1-888-9AGMEDNET or visit www.agmednet.com.
About ConforMIS, Inc.
ConforMIS, Inc. is a privately held company that develops and commercializes medical devices for the treatment of osteoarthritis and joint damages. The Company's novel and scaleable 'image-to-implant' process is comprised of two related technology platforms. iFit(tm) Technology enables the creation of conforming, patient-specific implants that are precisely sized and shaped to match the 3D topography of the patient's anatomy. iJig(tm) Instrumentation enables the creation of disposable, easy-to-use instrumentation that simplifies the surgical process and improves reproducibility.
Both platforms are supported by proprietary, intellectual property consisting of more than 120 patents and pending patent applications that span imaging software, image processing, implant design, surgical techniques and instrumentation.
To date, ConforMIS has developed a comprehensive line of minimally traumatic, bone and cartilage-preserving knee implants and instrumentation designed to address all stages of osteoarthritis. Each of these devices has been cleared by the US Food and Drug Administration for marketing in the U.S.
In 2008, ConforMIS was named the winner of the Red Herring North America 100 and the North American Frost & Sullivan Award for Medical Device Healthcare Innovation. For more information on ConforMIS visit www.conformis.com.